Table 2.
Baseline characteristics
| Cell injection (n = 19) |
Placebo (n = 20) |
P-value | |
|---|---|---|---|
| Age, mean ± SD, y | 65 ± 7 | 65 ± 8 | 0.61 |
| Men | 19 (100%) | 18 (90%) | 0.49 |
| Cardiovascular risk factors | |||
| Current smoking | 2 (11%) | 3 (15%) | 1.00 |
| History of smoking | 16 (84%) | 14 (70%) | 0.45 |
| Hypertension | 12 (63%) | 9 (45%) | 0.26 |
| Diabetes | 5 (26%) | 5 (25%) | 1.00 |
| Dyslipidaemia | 14 (74%) | 14 (70%) | 0.80 |
| Family history of CAD | 14 (74%) | 9 (45%) | 0.07 |
| BMI, mean ± SD, kg/m2 | 29 ± 5 | 29 ± 5 | 0.44 |
| Medication | |||
| Nitrates | 9 (47%) | 11 (55%) | 0.63 |
| Beta-blockers | 17 (89%) | 16 (80%) | 0.66 |
| Calcium channel blockers | 3 (16%) | 7 (35%) | 0.27 |
| Statins | 17 (89%) | 15 (75%) | 0.41 |
| ACE inhibitors | 12 (63%) | 12 (60%) | 0.84 |
| ATII antagonist | 9 (47%) | 7 (35%) | 0.43 |
| Clopidogrel | 2 (11%) | 6 (30%) | 0.24 |
| Aspirin | 3 (16%) | 9 (45%) | 0.05 |
| OAC | 16 (84%) | 11 (55%) | 0.05 |
| Diuretics | 15 (79%) | 15 (75%) | 1.00 |
| Medical history | |||
| ICD | 15 (79%) | 14 (70%) | 0.72 |
| PM | 1 (5%) | 0 (0%) | 0.49 |
| Biventricular pacing | 5 (26%) | 6 (30%) | 0.80 |
| Prior MI | 18 (95%) | 20 (100%) | 0.49 |
| Prior CABG | 12 (63%) | 12 (60%) | 0.84 |
| Prior PCI | 11 (58%) | 14 (70%) | 0.43 |
| Prior CVA/TIA | 2 (11%) | 3 (15%) | 1.00 |
IDDM insulin-dependent diabetes mellitus, NIDDM non-insulin-dependent diabetes mellitus, CAD coronary artery disease, BMI body mass index, ACE angiotensin-converting enzyme, AT angiotensin, OAC oral anticoagulants, ICD internal cardiac defibrillator, PM pacemaker, MI myocardial infarction, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, CVA/TIA cerebrovascular accident/transient ischaemic attack